PMID- 29878361
OWN - NLM
STAT- MEDLINE
DCOM- 20180919
LR  - 20180919
IS  - 1096-9098 (Electronic)
IS  - 0022-4790 (Linking)
VI  - 118
IP  - 1
DP  - 2018 Jul
TI  - Association between Ki-67 expression and clinical outcomes among patients with
      clinically node-negative, thick primary melanoma who underwent nodal staging.
PG  - 150-156
LID - 10.1002/jso.25111 [doi]
AB  - BACKGROUND: Patients with thick primary melanomas (>/=4 mm) have highly variable 
      survival outcomes. Cell proliferation marker Ki-67 has been identified as
      promising biomarker in thick melanoma but has not been evaluated since the wide
      spread adoption of sentinel lymph node biopsy. We revisit its prognostic
      relevance in the sentinel node era. METHODS: We studied patients with thick (>/=4
      mm) primary melanoma prospectively enrolled in a clinicopathological biospecimen 
      database from 2002 to 2015, and evaluated the prognostic value of Ki-67
      expression while controlling for features included in the existing staging
      criteria. RESULTS: We analyzed 68 patients who underwent lymph node sampling and 
      who had an available tumor for Ki-67 immunohistochemical (IHC) staining. The
      median tumor thickness was 6.0 mm; the median follow-up was 2.6 years. In
      multivariable analysis including nodal status and primary tumor ulceration, Ki-67
      expression was an independent predictor of worse recurrence-free survival (HR
      2.19, P = 0.024) and overall survival (HR 2.49, P = 0.028). Natural
      log-transformed tumor thickness (ln [thickness]) was also significantly
      associated with worse OS (HR 2.39, P = 0.010). CONCLUSION: We identify Ki-67 and 
      ln (thickness) as potential biomarkers for patients with thick melanoma who have 
      undergone nodal staging. If validated in additional studies, these biomarkers
      could be integrated into the staging criteria to improve risk-stratification.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Robinson, Eric M
AU  - Robinson EM
AD  - The Ronald O. Perelman Department of Dermatology, New York University School of
      Medicine, New York, New York.
FAU - Rosenbaum, Brooke E
AU  - Rosenbaum BE
AD  - The Ronald O. Perelman Department of Dermatology, New York University School of
      Medicine, New York, New York.
FAU - Zhang, Yilong
AU  - Zhang Y
AD  - Department of Population Health, New York University School of Medicine, New
      York, New York.
FAU - Rogers, Robert
AU  - Rogers R
AD  - Department of Pathology, New York University School of Medicine, New York, New
      York.
FAU - Tchack, Jeremy
AU  - Tchack J
AD  - The Ronald O. Perelman Department of Dermatology, New York University School of
      Medicine, New York, New York.
FAU - Berman, Russell S
AU  - Berman RS
AD  - Division of Surgical Oncology, Department of Surgery, Perlmutter Cancer Center,
      New York University School of Medicine, New York, New York.
FAU - Darvishian, Farbod
AU  - Darvishian F
AD  - Department of Pathology, New York University School of Medicine, New York, New
      York.
FAU - Osman, Iman
AU  - Osman I
AD  - The Ronald O. Perelman Department of Dermatology, New York University School of
      Medicine, New York, New York.
FAU - Shapiro, Richard L
AU  - Shapiro RL
AD  - Division of Surgical Oncology, Department of Surgery, Perlmutter Cancer Center,
      New York University School of Medicine, New York, New York.
FAU - Shao, Yongzhao
AU  - Shao Y
AD  - Department of Population Health, New York University School of Medicine, New
      York, New York.
FAU - Polsky, David
AU  - Polsky D
AUID- ORCID: http://orcid.org/0000-0001-9554-5289
AD  - The Ronald O. Perelman Department of Dermatology, New York University School of
      Medicine, New York, New York.
LA  - eng
GR  - 2P30CA16087/NYU Cancer Center Support Grant
PT  - Journal Article
DEP - 20180607
PL  - United States
TA  - J Surg Oncol
JT  - Journal of surgical oncology
JID - 0222643
RN  - 0 (Ki-67 Antigen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Ki-67 Antigen/*biosynthesis
MH  - Lymph Nodes/*pathology
MH  - Male
MH  - Melanoma/*metabolism/*pathology
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Sentinel Lymph Node Biopsy
MH  - Survival Rate
OTO - NOTNLM
OT  - Ki-67
OT  - T4 melanoma
OT  - sentinel lymph node
OT  - survival
EDAT- 2018/06/08 06:00
MHDA- 2018/09/20 06:00
CRDT- 2018/06/08 06:00
PHST- 2018/02/12 00:00 [received]
PHST- 2018/04/25 00:00 [accepted]
PHST- 2018/06/08 06:00 [pubmed]
PHST- 2018/09/20 06:00 [medline]
PHST- 2018/06/08 06:00 [entrez]
AID - 10.1002/jso.25111 [doi]
PST - ppublish
SO  - J Surg Oncol. 2018 Jul;118(1):150-156. doi: 10.1002/jso.25111. Epub 2018 Jun 7.